The NHANES study contains objectively measured physical activity data collected using hip-worn accelerometers from multiple cohorts. However, using the accelerometry data has proven daunting because: 1) currently, there are no agreed upon standard protocols for data storage and analysis; 2) data exhibit heterogeneous patterns of missingness due to varying degrees of adherence to wear-time protocols; 3) sampling weights need to be carefully adjusted and accounted for in individual analyses; 4) there is a lack of reproducible software that transforms the data from its published format into analytic form; and 5) the high dimensional nature of accelerometry data complicates analyses. Here, we provide a framework for processing, storing, and analyzing the NHANES accelerometry data for the 2003-2004 and 2005-2006 surveys. We also provide an NHANES data package in R, to help disseminate high quality, processed activity data combined with mortality and demographic information. Thus, we provide the tools to transition from "available data online" to "easily accessible and usable data", which substantially reduces the large upfront costs of initiating studies of association between physical activity and human health outcomes using NHANES. We apply these tools in an analysis showing that accelerometry features have the potential to predict 5-year all cause mortality better than known risk factors such as age, cigarette smoking, and various comorbidities.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7012355 | PMC |
http://dx.doi.org/10.1007/s12561-018-09229-9 | DOI Listing |
Background: Alzheimer's disease (AD) agitation is a distressing neuropsychiatric symptom characterized by excessive motor activity, verbal aggression, or physical aggression. Agitation is one of the causes of caregiver distress, increased morbidity and mortality, and early institutionalization in patients with AD. Current medications used for the management of agitation have modest efficacy and have substantial side effects.
View Article and Find Full Text PDFBackground: Alzheimer's disease (AD) is the most common cause of dementia worldwide. It is characterized by dysfunction in the U1 small nuclear ribonucleoproteins (snRNPs) complex, which may precede TAU aggregation, enhancing premature polyadenylation, spliceosome dysfunction, and causing cell cycle reentry and death. Thus, we evaluated the effects of a synthetic single-stranded cDNA, called APT20TTMG, in induced pluripotent stem cells (iPSC) derived neurons from healthy and AD donors and in the Senescence Accelerated Mouse-Prone 8 (SAMP8) model.
View Article and Find Full Text PDFBackground: CT1812 is an experimental therapeutic sigma-2 receptor modulator in development for Alzheimer's disease (AD) and dementia with Lewy bodies. CT1812 reduces the affinity of Aβ oligomers to bind to neurons and exert synaptotoxic effects. This phase 2, multi-center, international, randomized, double-blind, placebo-controlled trial assessed safety, tolerability and effects of CT1812 on cognitive function in individuals with AD.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
University of Florida / Center for Translational Research in Neurodegenerative Disease, Gainesville, FL, USA.
Background: Vaxxinity is developing an active immunotherapy targeting Tau for Alzheimer's disease (AD) and other tauopathies. VXX-301 is a multi-epitope vaccine designed to target the N-terminal and repeat domains of Tau. This design enables targeting multiple forms of Tau thought to contribute to Tau associated pathologies.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
EQT Life Sciences Partners, Amsterdam, 1071 DV Amsterdam, Netherlands.
Background: Alzheimer's disease (AD) trials report a high screening failure rate (potentially eligible trial candidates who do not meet inclusion/exclusion criteria during screening) due to multiple factors including stringent eligibility criteria. Here, we report the main reasons for screening failure in the 12-week screening phase of the ongoing evoke (NCT04777396) and evoke+ (NCT04777409) trials of semaglutide in early AD.
Method: Key inclusion criteria were age 55-85 years; mild cognitive impairment due to AD (Clinical Dementia Rating [CDR] global score of 0.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!